Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine

HIROYUKI TAKEDA; MASASHI OKADA; SHUHEI SUZUKI; KENTA KURAMOTO; HIROTSUGU SAKAKI; HIKARU WATARAI; TOMOMI SANOMACHI; SHIZUKA SEINO; TAKASHI YOSHIOKA; CHIFUMI KITANAKA

Research ArticleExperimental Studies

Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine

HIROYUKI TAKEDA, MASASHI OKADA, SHUHEI SUZUKI, KENTA KURAMOTO, HIROTSUGU SAKAKI, HIKARU WATARAI, TOMOMI SANOMACHI, SHIZUKA SEINO, TAKASHI YOSHIOKA and CHIFUMI KITANAKA

Anticancer Research December 2016, 36 (12) 6311-6318;

HIROYUKI TAKEDA

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

2Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MASASHI OKADA

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: ckitanak{at}med.id.yamagata-u.ac.jp m-okada{at}med.id.yamagata-u.ac.jp

SHUHEI SUZUKI

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

2Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KENTA KURAMOTO

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HIROTSUGU SAKAKI

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

3Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HIKARU WATARAI

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

4Second Department of Surgery, Yamagata University School of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOMOMI SANOMACHI

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

SHIZUKA SEINO

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

5Research Institute for Promotion of Medical Sciences, Yamagata University Faculty of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TAKASHI YOSHIOKA

2Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

CHIFUMI KITANAKA

1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan

5Research Institute for Promotion of Medical Sciences, Yamagata University Faculty of Medicine, Yamagata, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: ckitanak{at}med.id.yamagata-u.ac.jp m-okada{at}med.id.yamagata-u.ac.jp

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 36 no. 12 6311-6318

PMID

27919951

Published By

International Institute of Anticancer Research

Print ISSN

0250-7005

Online ISSN

1791-7530

History

Received September 19, 2016
Revision received October 5, 2016
Accepted October 10, 2016
Published online December 5, 2016.

Author Information

HIROYUKI TAKEDA¹,²,*,
MASASHI OKADA¹,*⇑,
SHUHEI SUZUKI¹,²,
KENTA KURAMOTO¹,
HIROTSUGU SAKAKI¹,³,
HIKARU WATARAI¹,⁴,
TOMOMI SANOMACHI¹,
SHIZUKA SEINO¹,⁵,
TAKASHI YOSHIOKA² and
CHIFUMI KITANAKA¹,⁵ ⇑

¹Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan
²Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan
³Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan
⁴Second Department of Surgery, Yamagata University School of Medicine, Yamagata, Japan
⁵Research Institute for Promotion of Medical Sciences, Yamagata University Faculty of Medicine, Yamagata, Japan

Correspondence to: Chifumi Kitanaka and Masashi Okada, Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, 990-9585, Japan. Tel: +81 236285212, Fax: +81 236285215, e-mail: ckitanak{at}med.id.yamagata-u.ac.jp, m-okada{at}med.id.yamagata-u.ac.jp

View Full Text

Statistics from Altmetric.com

Cited By...

32 Citations
Citations
Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext

In this issue

Anticancer Research

Vol. 36, Issue 12

December 2016

Table of Contents
Table of Contents (PDF)
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 5 + 6 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine

HIROYUKI TAKEDA, MASASHI OKADA, SHUHEI SUZUKI, KENTA KURAMOTO, HIROTSUGU SAKAKI, HIKARU WATARAI, TOMOMI SANOMACHI, SHIZUKA SEINO, TAKASHI YOSHIOKA, CHIFUMI KITANAKA

Anticancer Research Dec 2016, 36 (12) 6311-6318;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine

HIROYUKI TAKEDA, MASASHI OKADA, SHUHEI SUZUKI, KENTA KURAMOTO, HIROTSUGU SAKAKI, HIKARU WATARAI, TOMOMI SANOMACHI, SHIZUKA SEINO, TAKASHI YOSHIOKA, CHIFUMI KITANAKA

Anticancer Research Dec 2016, 36 (12) 6311-6318;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

LncRNA LINC00941 Links Oncogenic KRAS Signaling to Aggressiveness and Chemoresistance in Pancreatic Cancer
Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis
AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel
A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel
Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response
Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents

Google Scholar

Keywords

ROK
chemosensitization
apoptosis
combination chemotherapy

Main menu

User menu

Search

Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine

Article Information

Author Information

Statistics from Altmetric.com

Cited By...

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords